Cancer Vaccines (Conference News)

Modified Vaccinia Vector Shows Promise As Cancer Vaccine

Published in Gene Therapy Weekly, November 24th, 1997

In vitro results from using a replication deficient vaccinia virus, modified to express the human tyrosinase as a tumor associated antigen (TAA) as a cancer vaccine, are promising.

I. Drexler, representing colleagues from the Institute for Molecular Virology, the Technical University of Dresden, and the Johannes Gutenberg-University, Germany, presented results at the 3rd European Conference on Gene Therapy of Cancer, held September 11-13, 1997, in Berlin, Germany, suggesting that the modified vaccinia virus Ankara (MVA) might have a successful future as a cancer immunotherapeutic.

"The modified vaccinia virus Ankara, a highly attenuated vaccinia...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1997-11-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry